Abattis Bioceuticals (ATTBF) 0.1500 $ATTBF
Abattis Retains J2 Response as a Marketing Partner
Marketwired - Tue Feb 10, 2:02PM CST
Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTCQX: ATTBF) (CSE: ATT), a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, would like to announce that Abattis has retained J2Response as a marketing partner.
BioCell Labs Initiates Product Development
Marketwired - Tue Feb 10, 1:51PM CST
Abattis Bioceuticals Corp. (the "Company" or "Abattis" (OTCQX: ATTBF) (CSE: ATT), a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, would like to announce that through it's wholly owned subsidiary, Biocell Labs, Inc., a Marketing agenda to deliver Hemp-based nutraceutical supplements to the licensed health care provider marketplace. Currently, the wholly owned subsidiary has 13 proprietary formulations for out-licensing to cosmetic, nutraceutical and pharmaceutical companies.
A Preliminary Examination Of N=35 Canadian Marijuana Stocks... Eh?
Anthony Cataldo - at Seeking Alpha - Mon Feb 09, 3:20AM CST
117 Marijuana Stocks For Your Do Not 'Buy-And-Hold' List
Anthony Cataldo - at Seeking Alpha - Fri Feb 06, 10:14AM CST
GWPH: 78.09 (+1.70), FULL: 4.40 (+0.06), CARA: 10.96 (-0.03)
Abattis Enters Into US$25 Million Equity Line Facility Agreement with Dutchess Opportunity Fund, II, LP
Marketwired - Wed Feb 04, 1:36PM CST
Abattis Bioceuticals Corp. (the "Company" or "Abattis" (OTCQX: ATTBF)(CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, including medical marihuana, announced that it has entered into a US$25 million equity line facility agreement with Dutchess Opportunity Fund, II, LP, a Delaware Limited Partnership - ("Dutchess" . The Company has agreed to file a registration statement with the U.S. Securities & Exchange Commission ("SEC" covering the Abattis shares that may be issued to Dutchess under this financing. After the SEC has declared the registration statement related to the transaction effective, the Company has the right at its sole discretion over a period of three years to sell up to US$25 million of common shares to Dutchess under the terms of the financing agreement, which shares will be issued at the current market price less permitted discounts in effect during such issuances. Proceeds from this transaction will be used to fund the continued development of the Company's GDERS (grow, dry, extract, refine, sell) strategy spanning the entire industry supply chain from seed to sale.
Abattis Seeks Financing Solutions to Facilitate New Growth Initiative: Abattis Ends US$5 Million Standby Equity Purchase Agreement With Kodiak Capital Group LLC
Marketwired - Wed Feb 04, 1:11PM CST
Abattis Bioceuticals Corp. (the "Company" or "Abattis" (OTCQX: ATTBF)(CSE: ATT), announced that the standby equity financing agreement and a registration rights agreement with Kodiak Capital Group, LLC announced on August 5, 2014, in order to establish a possible source of funding for us has been terminated. Under the equity financing agreement, Kodiak agreed to provide us with up to $5,000,000 of funding upon effectiveness of a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission. The Company did not file a Form F-1 or sell any shares of its common stock under the equity financing agreement.
Abattis Announces New Corporate Communications Appointment
ACCESSWIRE - Wed Feb 04, 8:08AM CST
Vancouver, BC / ACCESSWIRE / February 4, 2015 / Abattis Bioceuticals Corp. (the "Company" or "Abattis" (OTCQX: ATTBF) (CSE: ATT), a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, would like to announce the resignation of Saf Dhillon and welcome Michael Bessler as corporate communications consultant for the Company.
Abattis CEO - A Letter To Shareholders
ACCESSWIRE - Tue Feb 03, 7:49AM CST
Vancouver, BC / ACCESSWIRE / February 3, 2015 / Abattis Bioceuticals Corp. (the "Company" or "Abattis" (OTCQX: ATTBF) (CSE: ATT), provides a letter to shareholder from William ("Bill" Fleming, Chief Executive Officer ("CEO" .
Abattis CEO-A Letter to Shareholders
Marketwired - Tue Feb 03, 7:32AM CST
Abattis Bioceuticals Corp. (the "Company" or "Abattis" (OTCQX: ATTBF)(CSE: ATT), provides a letter to shareholder from William ("Bill" Fleming, Chief Executive Officer ("CEO" .
99 Marijuana Stocks For Your Do Not 'Buy And Hold' List
Anthony Cataldo - at Seeking Alpha - Mon Feb 02, 6:25AM CST
GWPH: 78.09 (+1.70), FULL: 4.40 (+0.06), CARA: 10.96 (-0.03), ICN: 21.26 (-0.05)
Marijuana Firms - Exploring N=99, Ranked By Market Capitalization
Anthony Cataldo - at Seeking Alpha - Mon Feb 02, 3:34AM CST
GWPH: 78.09 (+1.70), FULL: 4.40 (+0.06), CARA: 10.96 (-0.03)
Abattis Retains J2 Response as a Marketing Partner
Marketwired - Tue Feb 10, 2:02PM CST
Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTCQX: ATTBF) (CSE: ATT), a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, would like to announce that Abattis has retained J2Response as a marketing partner. BioCell Labs Initiates Product Development
Marketwired - Tue Feb 10, 1:51PM CST
Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTCQX: ATTBF) (CSE: ATT), a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, would like to announce that through it's wholly owned subsidiary, Biocell Labs, Inc., a Marketing agenda to deliver Hemp-based nutraceutical supplements to the licensed health care provider marketplace. Currently, the wholly owned subsidiary has 13 proprietary formulations for out-licensing to cosmetic, nutraceutical and pharmaceutical companies. A Preliminary Examination Of N=35 Canadian Marijuana Stocks... Eh?
Anthony Cataldo - at Seeking Alpha - Mon Feb 09, 3:20AM CST
117 Marijuana Stocks For Your Do Not 'Buy-And-Hold' List
Anthony Cataldo - at Seeking Alpha - Fri Feb 06, 10:14AM CST
GWPH: 78.09 (+1.70), FULL: 4.40 (+0.06), CARA: 10.96 (-0.03)
Abattis Enters Into US$25 Million Equity Line Facility Agreement with Dutchess Opportunity Fund, II, LP
Marketwired - Wed Feb 04, 1:36PM CST
Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTCQX: ATTBF)(CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, including medical marihuana, announced that it has entered into a US$25 million equity line facility agreement with Dutchess Opportunity Fund, II, LP, a Delaware Limited Partnership - ("Dutchess" . The Company has agreed to file a registration statement with the U.S. Securities & Exchange Commission ("SEC" covering the Abattis shares that may be issued to Dutchess under this financing. After the SEC has declared the registration statement related to the transaction effective, the Company has the right at its sole discretion over a period of three years to sell up to US$25 million of common shares to Dutchess under the terms of the financing agreement, which shares will be issued at the current market price less permitted discounts in effect during such issuances. Proceeds from this transaction will be used to fund the continued development of the Company's GDERS (grow, dry, extract, refine, sell) strategy spanning the entire industry supply chain from seed to sale. Abattis Seeks Financing Solutions to Facilitate New Growth Initiative: Abattis Ends US$5 Million Standby Equity Purchase Agreement With Kodiak Capital Group LLC
Marketwired - Wed Feb 04, 1:11PM CST
Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTCQX: ATTBF)(CSE: ATT), announced that the standby equity financing agreement and a registration rights agreement with Kodiak Capital Group, LLC announced on August 5, 2014, in order to establish a possible source of funding for us has been terminated. Under the equity financing agreement, Kodiak agreed to provide us with up to $5,000,000 of funding upon effectiveness of a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission. The Company did not file a Form F-1 or sell any shares of its common stock under the equity financing agreement. Abattis Announces New Corporate Communications Appointment
ACCESSWIRE - Wed Feb 04, 8:08AM CST
Vancouver, BC / ACCESSWIRE / February 4, 2015 / Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTCQX: ATTBF) (CSE: ATT), a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, would like to announce the resignation of Saf Dhillon and welcome Michael Bessler as corporate communications consultant for the Company. Abattis CEO - A Letter To Shareholders
ACCESSWIRE - Tue Feb 03, 7:49AM CST
Vancouver, BC / ACCESSWIRE / February 3, 2015 / Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTCQX: ATTBF) (CSE: ATT), provides a letter to shareholder from William ("Bill" Fleming, Chief Executive Officer ("CEO" . Abattis CEO-A Letter to Shareholders
Marketwired - Tue Feb 03, 7:32AM CST
Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTCQX: ATTBF)(CSE: ATT), provides a letter to shareholder from William ("Bill" Fleming, Chief Executive Officer ("CEO" . 99 Marijuana Stocks For Your Do Not 'Buy And Hold' List
Anthony Cataldo - at Seeking Alpha - Mon Feb 02, 6:25AM CST
GWPH: 78.09 (+1.70), FULL: 4.40 (+0.06), CARA: 10.96 (-0.03), ICN: 21.26 (-0.05)
Marijuana Firms - Exploring N=99, Ranked By Market Capitalization
Anthony Cataldo - at Seeking Alpha - Mon Feb 02, 3:34AM CST
GWPH: 78.09 (+1.70), FULL: 4.40 (+0.06), CARA: 10.96 (-0.03)
